Vogel, A., Saborowski, A., Wenzel, P., Wege, H., Folprecht, G., Kretzschmar, A., . . . Kirstein, M. M. (2024). Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): A multicentre, open-label, randomised, phase 2 trial. The lancet. Gastroenterology & Hepatology, 9(8), . https://doi.org/10.1016/S2468-1253(24)00119-5
Chicago-Zitierstil (17. Ausg.)Vogel, Arndt, et al. "Nanoliposomal Irinotecan and Fluorouracil Plus Leucovorin Versus Fluorouracil Plus Leucovorin in Patients with Cholangiocarcinoma and Gallbladder Carcinoma Previously Treated with Gemcitabine-based Therapies (AIO NALIRICC): A Multicentre, Open-label, Randomised, Phase 2 Trial." The Lancet. Gastroenterology & Hepatology 9, no. 8 (2024). https://doi.org/10.1016/S2468-1253(24)00119-5.
MLA-Zitierstil (9. Ausg.)Vogel, Arndt, et al. "Nanoliposomal Irinotecan and Fluorouracil Plus Leucovorin Versus Fluorouracil Plus Leucovorin in Patients with Cholangiocarcinoma and Gallbladder Carcinoma Previously Treated with Gemcitabine-based Therapies (AIO NALIRICC): A Multicentre, Open-label, Randomised, Phase 2 Trial." The Lancet. Gastroenterology & Hepatology, vol. 9, no. 8, 2024, https://doi.org/10.1016/S2468-1253(24)00119-5.